問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chi Mei Medical Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 710Tainan CityTainan Yongkang

Recruiting Trial

138Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

418Cases

2012-02-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-08-30 - 2014-07-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Terminated17Sites

2007-08-08 - 2008-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-01-01 - 2013-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)

  • Condition/Disease

    Acute Coronary Symdrome

  • Test Drug

    SCH530348

Participate Sites
13Sites

Terminated13Sites

2007-01-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-07-01 - 2021-11-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

2016-08-01 - 2018-12-31

Phase III

A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

  • Condition/Disease

    carbapenem-resistant Gram-negative bacterial infections

  • Test Drug

    S-649266

Participate Sites
7Sites

Terminated7Sites

2017-01-01 - 2020-02-29

Phase III

A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Influenza Complications

  • Condition/Disease

    Influenza

  • Test Drug

    S-033188

Participate Sites
11Sites

Terminated11Sites

2007-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-11-01 - 2021-12-31

Phase III

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection

  • Condition/Disease

    C. difficile Infection

  • Test Drug

    C. difficile Toxoid Vaccine

Participate Sites
7Sites

Terminated7Sites

1 29 30 31 32 33 42
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB